EXCLI Journal; 17:Doc598; ISSN 1611-2156 2018
DOI: 10.17179/excli2018-1325
|View full text |Cite
|
Sign up to set email alerts
|

Targeting PPAR-γ to design and synthesize antidiabetic thiazolidines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 13 publications
0
1
0
Order By: Relevance
“…Several heterocyclic compounds have been observed to have a significant role in the chemotherapy of malignancy. 18 Although 2,4-dioxothiazolidines have been reported to be a potential platform because they are known to stimulate the PPARγ 19 receptor, they also have multiple PPARγ independent effects, and the dose required for anticancer activity of 2,4-dioxothiazolidines is significantly lower than that required for hypoglycemic activity.…”
Section: Introductionmentioning
confidence: 99%
“…Several heterocyclic compounds have been observed to have a significant role in the chemotherapy of malignancy. 18 Although 2,4-dioxothiazolidines have been reported to be a potential platform because they are known to stimulate the PPARγ 19 receptor, they also have multiple PPARγ independent effects, and the dose required for anticancer activity of 2,4-dioxothiazolidines is significantly lower than that required for hypoglycemic activity.…”
Section: Introductionmentioning
confidence: 99%